Shots:

• The P-III TULIP 2 study involves assessing of anifrolumab (300mg- FD- IV) vs PBO in 373 patients in ratio (1:1) for adults with moderate-to-severe SLE and has demonstrated meeting its 1EPs with reduction in disease activity which was assessed using BICLA @52 wks. and the safety profile was also consistent with previous trials
•  The P-III TULIP program involves two P-III trials (TULIP 1- TULIP 2) assessing anifrolumab (150mg/300mg) vs PBO in patients with SLE in ratio (1:2:2) & (1:1) evaluating the effect of anifrolumab in reducing disease activity measured by SRI4 and BICLA respectively
• Anifrolumab is a mAb that binds to subunit 1 of the type I interferon receptor further blocking its interaction with Type I interferons including IFN-alpha- IFN-beta and IFN-omega. Additionally- the P-III TULIP study program includes a P-III long-term extension trial in SLE and a P-II trial in lupus nephritis

Click here to read full press release/ article

 Ref: AstraZeneca | Image: AstraZeneca